Clinical Trials Browser

Borderline Resectable Pancreatic Adenocarcinoma × Irinotecan × Clear all

NCT04481204 2026-04-15

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase 2 Active not recruiting

Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT03970252 2024-08-09

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Phase EARLY_PHASE1 Completed

Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma